Abstract: This invention provides a vaccine comprising (i) an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject and (ii) a pharmaceutically acceptable carrier. This invention provides a vaccine comprising (i) a conjugate of an anthrose-containing saccharide in an amount effective to enhance immunity against Bacillus anthracis in a subject, wherein the anthrose-containing saccharide is conjugated to a biomolecule via a linker, and (ii) a pharmaceutically acceptable carrier.

Abstract: The present invention is directed to methods for coating monolayer films of surface-active polymers onto substrates of arbitrary shape. The present invention also provides molecular-based methods and processes that can be used to control the chemical and physical nature of surfaces and interfaces. The present invention is directed to methods for modifying functional groups in a homogenous way and controlling the spatial distributions of surface functional groups.

Abstract: A method for surface micropatterning includes forming on a surface containing a first polymer a first coating containing a second polymer having first functionalities capable of being converted to second functionalities by exposure to an acid. A second coating containing a photoacid generator is formed on the first coating. The second coating containing the photoacid generator is selectively irradiated in one or more regions thereof with radiation having a spatially varying internsity pattern to generate an acid in each irradiated region of the second coating. The acid converts the first functionalities of each region of the second polymer underlying a respective irradiated region of the second coating to second functionalities. A first molecular patterned surface having one or more regions of the first functionalities and one or more regions of the second functionalities is formed.

Abstract: Disclosed is a method for making ?,?-allyl terminated macromonomers comprising a plurality of units of an ?,?-unsaturated carboxylic acid. The method comprises forming a first mixture containing an ester of an ?,?-unsaturated carboxylic acid, a radical initiator comprising an allyl group and a halogen, and a catalyst comprising a transition metal complex. The ester of the ?,?-unsaturated carboxylic acid is an ester capable of reacting with a mixture comprising trifluoroacetic acid (TFA) to form the ?,?-unsaturated carboxylic acid. The mixture is stirred to form a second mixture containing an ?-allyl, ?-halogen-terminated macromonomer comprising a plurality of units of the ester of the ?,?-unsaturated carboxylic acid. A third mixture comprising a compound containing at least one transferable allyl group is then added to the second mixture to form a fourth mixture containing a first ?,?-allyl terminated macromonomer comprising a plurality of units of the ester of the ?,?-unsaturated carboxylic acid.

Abstract: A tissue/implant interface, comprising an implant and a bioactive polymer layer adjacent at least a portion of the outer surface of the implant, wherein the polymer layer contains at least one tissue response modifier covalently attached to the polymer layer or entrapped within the polymer layer in a quantity effective to control the tissue response at the site of implantation. Preferably, the at least one tissue response modifier controls inflammation, fibrosis, and/or neovascularization. Exemplary tissue response modifiers include, but are not limited to, steroidal and non-steroidal anti-inflammatory agents, anti-fibrotic agents, anti-proliferative agents, cytokines, cytokine inhibitors, neutralizing antibodies, adhesive ligands, and combinations thereof. Use of the various combinations of tissue response modifiers with bioactive polymers provides a simple, flexible and effective means to control the implant/tissue interphase, improving implant lifetime and function.

Abstract: A tissue/implant interface, comprising an implant and a bioactive polymer layer adjacent at least a portion of the outer surface of the implant, wherein the polymer layer contains at least one tissue response modifier covalently attached to the polymer layer or entrapped within the polymer layer in a quantity effective to control the tissue response at the site of implantation. Preferably, the at least one tissue response modifier controls inflammation, fibrosis, and/or neovascularization. Exemplary tissue response modifiers include, but are not limited to, steroidal and non-steroidal anti-inflammatory agents, anti-fibrotic agents, anti-proliferative agents, cytokines, cytokine inhibitors, neutralizing antibodies, adhesive ligands, and combinations thereof. Use of the various combinations of tissue response modifiers with bioactive polymers provides a simple, flexible and effective means to control the implant/tissue interphase, improving implant lifetime and function.